OVID Ovid Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1636651 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-78.0%
TTM net income YoY-18.7%
TTM EPS YoY—
Revenue 3-yr CAGR69.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-4,700.3%
Net margin-2,971.3%
FCF margin—
EBITDA margin-4,694.6%
Returns
ROE-35.4%
ROA-30.1%
ROIC (approx.)-52.1%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets10.6%
Debt / equity0.00x
Current ratio11.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.34x
Accruals ratio10.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $7.25M | $566,000 | $392,000 | $1.50M | $208.38M |
| R&D expense | $25.58M | $36.77M | $28.59M | $24.62M | $46.94M |
| SG&A expense | $24.11M | $25.68M | $31.09M | $32.43M | $37.23M |
| Operating income | -$42.44M | -$61.88M | -$59.28M | -$55.55M | $124.21M |
| Pretax income | -$17.41M | -$26.43M | -$52.34M | -$54.17M | $124.16M |
| Income tax | $0 | $0 | $0 | $0 | $1.33M |
| Net income | -$17.41M | -$26.43M | -$52.34M | -$54.17M | $122.83M |
| EBITDA | -$42.17M | -$61.27M | -$58.71M | -$55.04M | $124.45M |
| EPS (basic) | — | — | -0.74 | -0.77 | 1.78 |
| EPS (diluted) | — | — | -0.74 | -0.77 | 1.76 |
| Weighted avg. shares (diluted) | — | — | 70.58M | 70.42M | 68.07M |
| Balance sheet | |||||
| Cash & equivalents | $13.15M | $28.23M | $28.97M | $46.80M | $189.73M |
| Short-term investments | $56.48M | $26.77M | $78.79M | $84.13M | $0 |
| Current assets | $74.37M | $55.94M | $109.60M | $131.38M | $190.48M |
| PP&E, net | $252,000 | $433,000 | $769,000 | $1.15M | $242,757 |
| Intangibles | $0 | $100,000 | $200,000 | $222,100 | $164,092 |
| Total assets | $150.93M | $92.17M | $144.03M | $155.27M | $194.54M |
| Current liabilities | $8.29M | $10.52M | $11.47M | $6.99M | $14.80M |
| Total liabilities | $20.27M | $23.94M | $56.23M | $22.99M | $14.80M |
| Shareholders' equity | $130.66M | $68.23M | $87.80M | $132.27M | $179.75M |
| Shares outstanding | 130.18M | 71.01M | 70.69M | 70.47M | 70.36M |
| Cash flow statement | |||||
| Operating cash flow | -$38.33M | -$55.96M | -$45.78M | -$55.23M | $118.61M |
| Capital expenditure | $0 | $71,000 | $40,000 | $1.22M | $184,008 |
| Free cash flow | -$38.33M | -$56.03M | -$45.82M | -$56.45M | $118.43M |
| Investing cash flow | -$49.85M | $54.59M | -$2.58M | -$87.88M | -$1.82M |
| Financing cash flow | $75.21M | $622,000 | $30.54M | $180,658 | $904,082 |
| Depreciation & amortization | $273,000 | $613,000 | $568,000 | $512,505 | $237,079 |
| Stock-based compensation | $4.81M | $6.28M | $7.29M | $6.56M | $5.05M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.